[
  {
    "ts": null,
    "headline": "Eli Lilly to Invest Over $1 Billion in India to Expand Manufacturing Network",
    "summary": "Company seeks local partnerships to boost supply of key drugs including Mounjaro",
    "url": "https://finnhub.io/api/news?id=b5ce1918685b1905ff92c8266ac1242b6544b792e2d106dd54ce57bac4535294",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759785660,
      "headline": "Eli Lilly to Invest Over $1 Billion in India to Expand Manufacturing Network",
      "id": 136998828,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Company seeks local partnerships to boost supply of key drugs including Mounjaro",
      "url": "https://finnhub.io/api/news?id=b5ce1918685b1905ff92c8266ac1242b6544b792e2d106dd54ce57bac4535294"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly's $1 Billion India Gamble Signals Pharma's Next Global Power Shift",
    "summary": "As Trump's drug tariffs bite, Lilly doubles down on India to secure its manufacturing future",
    "url": "https://finnhub.io/api/news?id=f2079989d801e7ad82cd0910718870675f387d02d5a6dab2885cb3bb5bf05449",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759777038,
      "headline": "Eli Lilly's $1 Billion India Gamble Signals Pharma's Next Global Power Shift",
      "id": 136989144,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "As Trump's drug tariffs bite, Lilly doubles down on India to secure its manufacturing future",
      "url": "https://finnhub.io/api/news?id=f2079989d801e7ad82cd0910718870675f387d02d5a6dab2885cb3bb5bf05449"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Stock Rises 16% in a Week: Here's What You Should Know",
    "summary": "LLY shares have jumped 16% last week as Pfizer's landmark government deal boosted investor confidence across the pharma sector.",
    "url": "https://finnhub.io/api/news?id=88735d0fcb63a6cfb4e581b50d0e4d2668db1e9868c3c8c6eee0408602cc25e5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759773420,
      "headline": "Eli Lilly Stock Rises 16% in a Week: Here's What You Should Know",
      "id": 136989547,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "LLY shares have jumped 16% last week as Pfizer's landmark government deal boosted investor confidence across the pharma sector.",
      "url": "https://finnhub.io/api/news?id=88735d0fcb63a6cfb4e581b50d0e4d2668db1e9868c3c8c6eee0408602cc25e5"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Stock on the Move: What Sparked the 6% Jump in the Past Week?",
    "summary": "ABBV shares rose 6% last week as optimism swept the pharma sector after Pfizer's landmark drug-pricing deal with the Trump administration.",
    "url": "https://finnhub.io/api/news?id=5fcaf3a41fe0cdbdb83a5783564f188f7555554b2bd1b20dff5217998e180b68",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759759860,
      "headline": "AbbVie Stock on the Move: What Sparked the 6% Jump in the Past Week?",
      "id": 136989145,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "ABBV shares rose 6% last week as optimism swept the pharma sector after Pfizer's landmark drug-pricing deal with the Trump administration.",
      "url": "https://finnhub.io/api/news?id=5fcaf3a41fe0cdbdb83a5783564f188f7555554b2bd1b20dff5217998e180b68"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: Beyond Weight Loss",
    "summary": "Eli Lilly is riding a big trend.",
    "url": "https://finnhub.io/api/news?id=2567832c586898e94827202c2cdcd84b6a2547efd25eea089bdcf594f616a938",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759758960,
      "headline": "Eli Lilly: Beyond Weight Loss",
      "id": 136989146,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly is riding a big trend.",
      "url": "https://finnhub.io/api/news?id=2567832c586898e94827202c2cdcd84b6a2547efd25eea089bdcf594f616a938"
    }
  },
  {
    "ts": null,
    "headline": "My Top 5 Biotech Stocks Big Pharma Could Buy Next",
    "summary": "Many of the biotech stocks remain outside of Mr. Market's interest zone. Check out five biotech firms that may be of interest to Big Pharma players.",
    "url": "https://finnhub.io/api/news?id=0615cc217ad0cd350a198a8133c50199b31af463e4f96ab378a062934e7cccc8",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759757340,
      "headline": "My Top 5 Biotech Stocks Big Pharma Could Buy Next",
      "id": 136988239,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1146642361/image_1146642361.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Many of the biotech stocks remain outside of Mr. Market's interest zone. Check out five biotech firms that may be of interest to Big Pharma players.",
      "url": "https://finnhub.io/api/news?id=0615cc217ad0cd350a198a8133c50199b31af463e4f96ab378a062934e7cccc8"
    }
  },
  {
    "ts": null,
    "headline": "Zacks Value Trader Highlights: Pfizer, Merck, AbbVie, Eli Lilly and Novo Nordisk",
    "summary": "Zacks Value Trader weighs whether big pharma names like Pfizer, Merck, AbbVie, Eli Lilly and Novo Nordisk are genuine bargains or value traps.",
    "url": "https://finnhub.io/api/news?id=f3d1e325c8979e5c256a781877a0e5161cf834c3f44fa173ef7dd8a98274314c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759755780,
      "headline": "Zacks Value Trader Highlights: Pfizer, Merck, AbbVie, Eli Lilly and Novo Nordisk",
      "id": 136989147,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Zacks Value Trader weighs whether big pharma names like Pfizer, Merck, AbbVie, Eli Lilly and Novo Nordisk are genuine bargains or value traps.",
      "url": "https://finnhub.io/api/news?id=f3d1e325c8979e5c256a781877a0e5161cf834c3f44fa173ef7dd8a98274314c"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk: CagriSema Sets Potential Obesity Drug Development Comeback",
    "summary": "Novo Nordisk A/S faces competition in obesity drug development space; pipeline innovations & long-term outlook. Read why NVO stock is downgraded to Buy.",
    "url": "https://finnhub.io/api/news?id=7a0a4409307918b16cd8ef9b75cb9db4f00d73dc8ce36583dae8f0ecacef3630",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759753610,
      "headline": "Novo Nordisk: CagriSema Sets Potential Obesity Drug Development Comeback",
      "id": 136988006,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2223748053/image_2223748053.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Novo Nordisk A/S faces competition in obesity drug development space; pipeline innovations & long-term outlook. Read why NVO stock is downgraded to Buy.",
      "url": "https://finnhub.io/api/news?id=7a0a4409307918b16cd8ef9b75cb9db4f00d73dc8ce36583dae8f0ecacef3630"
    }
  },
  {
    "ts": null,
    "headline": "Trogenix lands $95m Series A, backed by Eli Lilly, for brain cancer therapy",
    "summary": "Trogenix’s platform uses an AAV packed with two payloads in a “Trojan horse” approach to cancer treatment.",
    "url": "https://finnhub.io/api/news?id=78edf0ce5e4b863c614542e4d02b01c4219c9141d95959a9336b241d5c632c84",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759750513,
      "headline": "Trogenix lands $95m Series A, backed by Eli Lilly, for brain cancer therapy",
      "id": 136989148,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Trogenix’s platform uses an AAV packed with two payloads in a “Trojan horse” approach to cancer treatment.",
      "url": "https://finnhub.io/api/news?id=78edf0ce5e4b863c614542e4d02b01c4219c9141d95959a9336b241d5c632c84"
    }
  },
  {
    "ts": null,
    "headline": "Onco360® Has Been Selected as a Specialty Pharmacy Partner for INLURIYO™ (imlunestrant)",
    "summary": "LOUISVILLE, Ky., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Eli Lilly for Inluriyo™ (imlunestrant), indicated for the treatment of adults with estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative, estrogen receptor-1 (ESR1)-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.1 This indication was a",
    "url": "https://finnhub.io/api/news?id=481e736b1689bc36e6a0a59140467fb24ffd56d2e859466537522715b5077c42",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759750200,
      "headline": "Onco360® Has Been Selected as a Specialty Pharmacy Partner for INLURIYO™ (imlunestrant)",
      "id": 136989149,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "LOUISVILLE, Ky., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Eli Lilly for Inluriyo™ (imlunestrant), indicated for the treatment of adults with estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative, estrogen receptor-1 (ESR1)-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.1 This indication was a",
      "url": "https://finnhub.io/api/news?id=481e736b1689bc36e6a0a59140467fb24ffd56d2e859466537522715b5077c42"
    }
  },
  {
    "ts": null,
    "headline": "4BIO Capital founded Trogenix secures £70 million Series A financing to drive clinical development of potentially curative therapies for aggressive cancers",
    "summary": "Trogenix was founded by 4BIO as a spinout from the University of Edinburgh alongside Professor Steve Pollard and Dr Ken Macnamara in 2023Trogenix's breakthrough Odysseus® platform targets cancer cells to deliver precision therapies with curative “one and done” potential across multiple aggressive, treatment-resistant cancers£70 million financing round led by IQ Capital with participation from new investors Eli Lilly and Company, Meltwind, LongeVC, and Calculus Capital London, United Kingdom, 6 O",
    "url": "https://finnhub.io/api/news?id=b1976a79b45fcda8908aec725997a31685cf4288f8e8efc95ea6889a9ea91fb9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759748700,
      "headline": "4BIO Capital founded Trogenix secures £70 million Series A financing to drive clinical development of potentially curative therapies for aggressive cancers",
      "id": 136989150,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Trogenix was founded by 4BIO as a spinout from the University of Edinburgh alongside Professor Steve Pollard and Dr Ken Macnamara in 2023Trogenix's breakthrough Odysseus® platform targets cancer cells to deliver precision therapies with curative “one and done” potential across multiple aggressive, treatment-resistant cancers£70 million financing round led by IQ Capital with participation from new investors Eli Lilly and Company, Meltwind, LongeVC, and Calculus Capital London, United Kingdom, 6 O",
      "url": "https://finnhub.io/api/news?id=b1976a79b45fcda8908aec725997a31685cf4288f8e8efc95ea6889a9ea91fb9"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly to invest over $1 billion in India in global expansion",
    "summary": "STORY: Eli Lilly will invest over $1 billion in India to boost manufacturing and supply through local drugmakers. That’s according to the pharmaceutical giant Monday. It wants to tap into a skilled workforce to bolster its global manufacturing expansion.The company said collaborations aim to increase the availability of Lilly's key drugs.This includes those for obesity, diabetes, Alzheimer's, cancer and autoimmune conditions.The company launched its blockbuster weight-loss drug Mounjaro in India this year.But it doesn’t currently operate its own manufacturing plant in the country. Lilly's investment plans in India come at a time when global drugmakers are rushing to boost U.S. manufacturing capacity.That’s after the Trump administration imposed a 100% tariff on imported branded drugs from October 1.Last month, Lilly itself announced a $5 billion investment in a new Virginia facility, part of its $27 billion five-year U.S. expansion plan.Meanwhile, its India launch of Mounjaro has helped increase awareness of obesity treatments…In a country projected to have the world's second-largest obese population by 2050.Sales there of both Mounjaro and rival Novo Nordisk’s Wegovy doubled within months of their launch.",
    "url": "https://finnhub.io/api/news?id=724968fc92c89ce093c8d5abb26976228e298eea6d4440e2b5202daebf7ff745",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759746656,
      "headline": "Eli Lilly to invest over $1 billion in India in global expansion",
      "id": 136989151,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "STORY: Eli Lilly will invest over $1 billion in India to boost manufacturing and supply through local drugmakers. That’s according to the pharmaceutical giant Monday. It wants to tap into a skilled workforce to bolster its global manufacturing expansion.The company said collaborations aim to increase the availability of Lilly's key drugs.This includes those for obesity, diabetes, Alzheimer's, cancer and autoimmune conditions.The company launched its blockbuster weight-loss drug Mounjaro in India this year.But it doesn’t currently operate its own manufacturing plant in the country. Lilly's investment plans in India come at a time when global drugmakers are rushing to boost U.S. manufacturing capacity.That’s after the Trump administration imposed a 100% tariff on imported branded drugs from October 1.Last month, Lilly itself announced a $5 billion investment in a new Virginia facility, part of its $27 billion five-year U.S. expansion plan.Meanwhile, its India launch of Mounjaro has helped increase awareness of obesity treatments…In a country projected to have the world's second-largest obese population by 2050.Sales there of both Mounjaro and rival Novo Nordisk’s Wegovy doubled within months of their launch.",
      "url": "https://finnhub.io/api/news?id=724968fc92c89ce093c8d5abb26976228e298eea6d4440e2b5202daebf7ff745"
    }
  },
  {
    "ts": null,
    "headline": "The Healthcare Stock Play That Could Make Millennials Rich",
    "summary": "This investment may also make baby boomers, and those from Gen X and Gen Z, rich as well.",
    "url": "https://finnhub.io/api/news?id=fc3842249be640fd7650e437062b05c7659f870429f6c7a9f2edcee6c2fc8a30",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759744440,
      "headline": "The Healthcare Stock Play That Could Make Millennials Rich",
      "id": 136989152,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "This investment may also make baby boomers, and those from Gen X and Gen Z, rich as well.",
      "url": "https://finnhub.io/api/news?id=fc3842249be640fd7650e437062b05c7659f870429f6c7a9f2edcee6c2fc8a30"
    }
  },
  {
    "ts": null,
    "headline": "Trogenix announces £70 million / $95 million Series A financing to drive clinical development of potentially curative therapies for aggressive cancers",
    "summary": "Trogenix's breakthrough Odysseus® platform targets cancer cells to deliver precision therapies with curative “one and done” potential across multiple aggressive, treatment-resistant cancersFinancing round led by IQ Capital with participation from founding investor 4BIO Capital, returning investors Cancer Research Horizons and the National Brain Tumor Society’s Brain Tumor Investment Fund, and new investors Eli Lilly and Company, Meltwind, LongeVC, and Calculus CapitalCancer Research Horizons’ la",
    "url": "https://finnhub.io/api/news?id=a1862ac08bf9b314257741b1f5ac74b6b26092197cf1031c9e2900119b1b00a1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759730400,
      "headline": "Trogenix announces £70 million / $95 million Series A financing to drive clinical development of potentially curative therapies for aggressive cancers",
      "id": 136989153,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Trogenix's breakthrough Odysseus® platform targets cancer cells to deliver precision therapies with curative “one and done” potential across multiple aggressive, treatment-resistant cancersFinancing round led by IQ Capital with participation from founding investor 4BIO Capital, returning investors Cancer Research Horizons and the National Brain Tumor Society’s Brain Tumor Investment Fund, and new investors Eli Lilly and Company, Meltwind, LongeVC, and Calculus CapitalCancer Research Horizons’ la",
      "url": "https://finnhub.io/api/news?id=a1862ac08bf9b314257741b1f5ac74b6b26092197cf1031c9e2900119b1b00a1"
    }
  }
]